期刊文献+

HIV-1膜蛋白抗原优化改造研究进展

原文传递
导出
摘要 HIV-1的外膜糖蛋白能与T细胞或单核/巨噬细胞表面的CD4受体分子结合,从而起始HIV感染靶细胞的生物学过程。由于HIV-1膜蛋白是中和抗体的主要作用靶位,因此成为HIV疫苗中不可缺少的组分。越来越多的研究表明:天然HIV-1膜蛋白不能激发有效的中和抗体,所以需要对膜蛋白进行优化改造,以提高中和表位的免疫原性。本文就近年来HIV-1膜蛋白抗原优化改造研究做一简要回顾以供参考。
出处 《国际病毒学杂志》 2007年第2期49-54,共6页 International Journal of Virology
  • 相关文献

参考文献48

  • 1Edward A. Belongia, and Allison L. Naleway. Smallpox Vaccine:The Good, the Bad, and the Ugly. Clin Med Res 2003; 1(2) : 87-92.
  • 2Koch M, Pancera M, Kwong PD, et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003; 313: 387-400.
  • 3Freed EO,Risser R. The role of envelope glycoprotein processing in murine leukemia virus infection. J Virol 1987; 61: 2852-2856.
  • 4Wyatt R. , Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280 (5371) : 1884-1888.
  • 5Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393(6686) : 648-659.
  • 6Cheryl AP. Glycosylation of the ENV Spike of Primate Immunodeficiency Virus and Antibody Neutralization. Current HIV Res 2004,2 : 243-254.
  • 7McCaffrey RA, Saunders C, Hensel M, et al. N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies. JVI 2003; 78(7) : 3279-3295.
  • 8Li Y, Bergeron JJ, Luo L, et al. Effects of inefficient cleavage of the signal sequence of HIV-1 gp120 on its association with calnexin,folding and intracellular transport. PNAS 1996; 93: 9606-9611.
  • 9Li Y, Luo L, Rasool N, and Kang CY. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. JVI 1993; 67: 584-588.
  • 10Li Y, Luo L, Thomas DY, and Kang CY. Control of expression,glycosylation and secretion of HIV-1 gp120 by homologous and heterologous signal sequences. Virology 1994; 204: 266-278.

二级参考文献16

  • 1Goulder P J, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection [J ]. Nature, 2001,412:334 - 338.
  • 2Chouquet C, Autran B, Gomard E, et al. Correlation between breadth of memory HIV-specific cytotoxic T cells,viral load and disease progression in HIV infection[J]. AIDS,2002,16:2399 - 2407.
  • 3Cmarko D, Boe S O, Scassellati C, et al. Rev inhibition strongly affects intracellular distribution of human immunodeficiency virus type 1 RNAs[J ]. J Virol, 2002,76:10473 - 10484.
  • 4Kong W,Tian C J, Liu B D, et al. Stable expression of primary human immunodeficiency virus type 1 structural gene products by use of a noncytopathic Sindbis virus vector[ J ]. J Virol, 2002,76:1143411439.
  • 5Zolotukhin A S, Michalowski D, Bear J, et al. PSF acts through the human immunodeficiency virus type 1 mRNA instability elements to regulate virus expression[ J ]. Mol Cell Biol,2003,23: 6618 - 6630.
  • 6Andre S, Seed B, Eberle J, et al. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage[ J ]. J Virol, 1998,72:1497 - 1503.
  • 7Xin K Q, Urabe M, Yang J, et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus[J]. Hum Gene Ther, 2001,12:1047- 1061.
  • 8Klinman D M, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines [ J ]. J Immunol,1997,158: 3635 - 3639.
  • 9Letvin NL. Strategies for an HIV vaccine. J Clin Invest,2002, 110: 15-20.
  • 10Bruce CB, Akrigg A, Sharpe SA, et al. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice. J Gen Virol, 1999,80:2621-2628.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部